<DOC>
	<DOCNO>NCT02788279</DOCNO>
	<brief_summary>This Phase III , multicenter , open-label , three-arm , randomize study participant unresectable locally advanced metastatic colorectal cancer ( CRC ) receive least two prior regimen cytotoxic chemotherapy metastatic disease . The study compare regorafenib , standard care therapy setting , cobimetinib plus atezolizumab atezolizumab monotherapy .</brief_summary>
	<brief_title>A Study Investigate Efficacy Safety Cobimetinib Plus Atezolizumab Atezolizumab Monotherapy Versus Regorafenib Participants With Metastatic Colorectal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diseasespecific inclusion criterion : Histologically confirm adenocarcinoma originate colon rectum ( Stage 4 American Joint Committee Cancer [ AJCC ] 7th edition ) Experienced disease progression intolerant least two systemic chemotherapy regimens metastatic colorectal cancer must include fluroropyrimidines , irinotecan , oxaliplatin ; adjuvant regimen consider one chemotherapy regimen metastatic disease participant disease recurrence within 6 month completion ; disease progression must occur within 3 month last systemic therapy administration General inclusion criterion : Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Anticipated life expectancy great equal ( &gt; = ) 3 month Adequate hematologic end organ function Women childbearing potential must agree appropriately use effective form contraception ( failure rate less [ &lt; ] 1 percent [ % ] per year ) treatment period 3 month last dose study drug Men must agree donate sperm intercourse female partner without use appropriate barrier contraception treatment period 3 month last dose study drug Provide archival newly obtain tumor tissue sample After approximate 5 % cap microsatellite ( MSI ) high participant reach , MSIstable patient eligible Once 50 % cap wildtype RAS reach , extend RASmutant participant eligible Major surgery radiotherapy within 21 day prior Cycle 1 Day 1 anticipation need procedure receive study treatment Treatment anticancer agent within 14 day prior Cycle 1 Day 1 Uncontrolled tumorrelated pain . Participants require narcotic pain medication must stable regimen study entry Uncontrolled pleural effusion , pericardial effusion ascites require repeat drainage every 28 day . Indwelling drainage catheter ( e.g. , PleurXÂ® ) allow Active untreated central nervous system ( CNS ) metastases excluded Prior therapy cancer immunotherapy , MEK inhibitor , regorafenib Participants active malignancy ( CRC ) prior malignancy within past 3 year exclude . Participants completely resect cutaneous melanoma ( early stage ) , basal cell carcinoma , cutaneous squamous cell carcinoma , cervical carcinoma insitu , breast carcinoma insitu , localized prostate cancer eligible Unstable angina , new onset angina within last 3 month , myocardial infarction within last 6 month current congestive heart failure New York Heart Association Class II high Left ventricular ejection fraction ( LVEF ) institutional low limit normal 50 % , whichever low Poorly control hypertension , define blood pressure consistently 150/90 millimeter Mercury ( mmHg ) despite optimal medical management Human Immunodeficiency Virus ( HIV ) infection Active tuberculosis infection Severe infection within 2 week prior Cycle 1 Day 1 Active chronic viral hepatitis B C infection History evidence retinal pathology ophthalmologic examination consider risk factor central serous retinopathy , retinal vein occlusion , neovascular macular degeneration Participants exclude currently risk factor define study protocol retinal vein occlusion History autoimmune disease History idiopathic pulmonary fibrosis , organize pneumonia , bronchiolitis obliterans , druginduced pneumonitis , idiopathic pneumonitis History organ transplantation include allogeneic bone marrow transplantation Inability swallow medication Malabsorption condition would alter absorption orally administer medication Pregnant , lactating , breastfeeding , intend become pregnant study Administration live , attenuate vaccine within 4 week randomization anticipation live attenuate vaccine require study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Locally advanced Metastatic colorectal adenocarcinoma</keyword>
</DOC>